Impact of Hormonal Treatments on Breast Cancer Risk in Women

Overview of Breast Cancer Incidence Related to Infertility Treatments

The incidence of breast cancer has been a growing concern, with approximately 2.3 million new cases diagnosed in 2022 alone, leading to 670,000 deaths worldwide (Zaman et al., 2025). Hormonal treatments, particularly those used in infertility therapies, have raised questions regarding their potential role as a risk factor for breast cancer. The use of gonadotropins, clomiphene citrate, and letrozole—common medications in infertility treatments—has led to scrutiny about their long-term effects on breast tissue and cancer risk.

Analysis of Population-Based Studies on Hormonal Fertility Medications

A systematic review conducted by Zaman et al. (2025) analyzed 15 studies involving 92,555 women, comparing those who underwent hormonal fertility treatments to control groups. The pooled risk ratios (RR) indicated no significant increase in breast cancer risk associated with hormonal fertility medications (RR=1.00, 95% CI: [0.97-1.02], p=0.83). This finding suggests that hormonal treatments may not be as detrimental as previously thought concerning breast cancer risk.

Table 1: Summary of Key Studies Analyzing Infertility Treatments and Breast Cancer Risk

Relationship Between Infertility Medications and Breast Cancer Development

The hormonal treatments used for infertility can vary significantly in their mechanisms of action and duration of use. Clomiphene citrate, for instance, is an estrogen receptor modulator, while gonadotropins directly stimulate ovarian function. Recent studies suggest that while there is no strong correlation between these treatments and breast cancer incidence, longer durations and higher doses of certain medications, particularly clomiphene citrate, may present a higher risk (Zaman et al., 2025).

Statistical Findings on Breast Cancer Risks from Fertility Drugs

Statistical analyses reveal a complex interplay between infertility treatments and breast cancer risk. Notable findings include:

1. Pooled Analysis: The absence of increased risk for breast cancer following hormonal treatments (Zaman et al., 2025).
2. Hazard Ratios (HR): A significant protective effect on breast cancer risk was noted in studies evaluating hazard ratios (HR=0.91, 95% CI: [0.88-0.94], p<0.001), suggesting a nuanced relationship that may favor certain populations (Zaman et al., 2025).
3. Sensitivity Analysis: Consistent findings across various models indicate that the methodologies used in studies are significant factors influencing heterogeneity (Zaman et al., 2025).

Table 2: Statistical Summary of Findings on Infertility Medications and Breast Cancer Risk

Implications for Clinical Practice and Future Research Directions

The findings from these studies provide critical insights for healthcare professionals involved in fertility treatments. Understanding the lack of significant correlation between hormonal treatments and increased breast cancer risk can help alleviate concerns for patients considering these therapies. However, the nuances associated with treatment duration and dosage warrant further investigation.

Moreover, future research should focus on:

• Longitudinal Studies: To assess the long-term effects of hormonal treatments on breast cancer risk.
• Diverse Populations: To ensure findings are generalizable across different demographics.
• Mechanistic Studies: To explore the biological pathways influencing breast cancer risk in the context of hormonal treatments.

Frequently Asked Questions (FAQ)

Do hormonal fertility treatments increase the risk of breast cancer?
Current research, including a meta-analysis of 15 studies, indicates no significant increase in breast cancer risk associated with hormonal fertility treatments (Zaman et al., 2025).

What are the common hormonal treatments for infertility?
Common hormonal treatments include clomiphene citrate, gonadotropins, and letrozole, which aim to stimulate ovarian function and promote ovulation.

Should women with a family history of breast cancer avoid hormonal fertility treatments?
While concerns exist, studies suggest that these treatments do not significantly elevate breast cancer risk, even for women with a family history (Zaman et al., 2025). However, it is crucial to consult with a healthcare provider for personalized advice.

What are the recommendations for future research?
Future studies should focus on long-term effects, diverse populations, and mechanistic insights into the interaction between hormonal treatments and breast cancer risk.

References

1. Zaman, A. Y., Alrefai, L. S., Alharbi, D. F., Khurmi, R. A., Abuanq, L. M., Aljohani, A. A., Dighriri, I. M. (2025). Breast cancer incidence after hormonal treatment for infertility: A meta-analysis of population-based studies. Saudi Medical Journal. https://doi.org/10.15537/smj.2025.46.5.20240544

2. Zaman, A. Y. (2025). Impact of technology- and parent-based psychosocial interventions on family dynamics factors in children with cancer: A systematic review. PLOS One. https://doi.org/10.1371/journal.pone.0323483

3. Zaman, A. Y., Elnugomi, N. (2025). Opportunities and challenges for plague vector control in Madagascar. PLOS Neglected Tropical Diseases. https://doi.org/10.1371/journal.pntd.0013054

4. Zaman, A. Y., et al. (2025). Shedding light on Brazil’s contribution to photobiomodulation research in oral medicine: a bibliometric study

5. Zaman, A. Y., et al. (2025). A decade of vertebrate palaeontology research: global taxa distribution, gender dynamics and evolving methodologies. https://doi.org/10.3390/jcm14092944

6. Zaman, A. Y. (2025)